Dipyridamole
Platelet aggregation inhibitors excl. heparin · given by injection, oral · on the market since 1990
What it's made of
Each functional group on the molecule does a specific, predictable job.
No standard functional groups matched.
Where it can get to
Predicted from molecular weight, lipophilicity, polar surface area and hydrogen-bond donor count. A drug can only act where it distributes, so this constrains which conditions are addressable before any biology is considered. derived
What it binds — and whether we can reach it · 6 of 7 reachable
Binding affinity is only meaningful against the plasma concentration reached at the approved dose. A target requiring higher concentrations cannot be engaged in a patient, whatever the in vitro potency. Most repurposing hypotheses fail at this step, and it is rarely checked before a trial is proposed. measured
| Target | Kind | Action | Affinity (pAct) | Can it be engaged? |
|---|---|---|---|---|
| SLC29A1 | Transporter | inhibitor | 8.5 | Engaged easily |
| PDE6D | Enzyme | inhibitor | 6.9 | Just reachable |
| PDE5A | Enzyme | inhibitor | 6.28 | Just reachable |
| PDE7A | Enzyme | inhibitor | 6.22 | Just reachable |
| PDE10A | Enzyme | inhibitor | 6 | Just reachable |
| PDE7B | Enzyme | inhibitor | 6 | Just reachable |
| PDE4A | Enzyme | inhibitor | 5.8 | Out of reach |
This molecule concentrates in urine. Local concentration therefore exceeds plasma, so targets that look unreachable on a plasma reading may still be engaged. assumed
New uses, and who is already trying them
One card per candidate indication: the reasoning link by link, the evidence tier that governs how strongly it can be stated, and any registered trials.
5 of the 72 conditions linked to this drug’s targets have been checked against trial records so far. The rest are not ruled out — they are unchecked.
3 possible uses were rejected for pushing the wrong way. The target is linked to the condition, but the drug modulates it in the wrong direction.
infantile-onset generalized dyskinesia with orofacia
Rejected — wrong wayIt would be expected to worsen this condition. The genetic evidence indicates this condition requires the opposite modulation of the target. Shown rather than filtered so the direction check can be audited.
striatal degeneration, autosomal dominant 2
Rejected — wrong wayIt would be expected to worsen this condition. The genetic evidence indicates this condition requires the opposite modulation of the target. Shown rather than filtered so the direction check can be audited.
Joubert syndrome with orofaciodigital defect
Rejected — wrong wayIt would be expected to worsen this condition. The genetic evidence indicates this condition requires the opposite modulation of the target. Shown rather than filtered so the direction check can be audited.
psoriasis
Mechanism implies itIt could plausibly help.
Established practice, listed so the method can be checked against what is already known.
coronary artery disorder
Already in useIt is already used for this.
Why nobody will fund it
8 companies make this across 17 approved products. With that many manufacturers the price has fallen to production cost. A company funding a trial could not recover it — competitors could market the same molecule for the new indication immediately, without contributing.
A new route or dosage form qualifies for a 505(b)(2) application, which carries three years of exclusivity for that formulation. It is the only remaining route to exclusivity on a generic molecule.
What it would cost to find out
Derived, not quoted. Events needed is 4(zα+zβ)²/ln(HR)²; enrolment is that divided by the event rate and follow-up. The 1/ln(HR)² term dominates: halving the detectable effect size roughly quadruples enrolment. derived
Cost per person reached is the relevant metric for a non-commercial funder, since there is no revenue to set against the outlay.
Ask for ideas nobody has listed
Reasons from the functional groups and distribution above, excluding conditions already listed. Output is hypotheses for falsification, not findings. Not medical advice.
Who might pay for the trial
Trials of off-patent drugs are rarely funded by venture capital or pharma. They are paid for by government grants and disease foundations. Here is who has funded work on this molecule before, what federal mechanisms are open now, and which foundations fund trials in the disease areas it touches. measured
Open notices with an explicit mandate to fund work on approved or off-patent molecules.
Grants.gov lists US federal money. Many off-patent drug trials are supported by disease foundations and nonprofits. These are matched to the body systems this drug touches. assumed
Who manufactures it
Companies holding an approved abbreviated application for this molecule in the United States, from the FDA Orange Book. Supply already exists at scale, so a trial would not need a manufacturing programme — but any of these could also be a partner, or an objector.
Nothing on this page is medical advice. Candidate uses are unproven hypotheses derived from public data; established uses are listed for verification only. Figures carry their provenance inline — anything marked assumed or derived is not a measurement.
← Back to the full ledger